Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICLR
stocks logo

ICLR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.01B
-1.38%
3.327
-3%
2.01B
+0.34%
3.264
+2.33%
2.02B
+0.04%
3.337
+2.35%
Estimates Revision
The market is revising Upward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by 1.09% over the past three months. During the same period, the stock price has changed by 6.23%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.14%
In Past 3 Month
Stock Price
Go Up
up Image
+6.23%
In Past 3 Month
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 185.770
sliders
Low
172.00
Averages
204.92
High
236.00
Current: 185.770
sliders
Low
172.00
Averages
204.92
High
236.00
BMO Capital
Sean Dodge
Market Perform
initiated
$175
2025-11-12
Reason
BMO Capital
Sean Dodge
Price Target
$175
2025-11-12
initiated
Market Perform
Reason
BMO Capital analyst Sean Dodge initiated coverage of Icon with a Market Perform rating and $175 price target. The firm's analysis suggests the company's cancellations are likely remain elevated for the next few quarters. However, it also indicates the worst is probably now behind Icon, the analyst tells investors in a research note.
Baird
NULL -> Outperform
maintain
$218 -> $220
2025-10-24
Reason
Baird
Price Target
$218 -> $220
2025-10-24
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Icon to $220 from $218 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
UBS
Buy -> Buy
downgrade
$240 -> $220
2025-10-24
Reason
UBS
Price Target
$240 -> $220
2025-10-24
downgrade
Buy -> Buy
Reason
UBS lowered the firm's price target on Icon to $220 from $240 and keeps a Buy rating on the shares.
TD Cowen
Charles Rhyee
Hold
downgrade
$183 -> $172
2025-10-24
Reason
TD Cowen
Charles Rhyee
Price Target
$183 -> $172
2025-10-24
downgrade
Hold
Reason
TD Cowen analyst Charles Rhyee lowered the firm's price target on Icon to $172 from $183 and keeps a Hold rating on the shares. The firm came away from the conference call still concerned on 2026 estimates, with management expecting margin pressure from pass-throughs to continue into 4Q and next year. Margin pressure from pricing is another headwind to 2026 that hasn't been felt yet.
Barclays
Equal Weight
downgrade
$190 -> $185
2025-10-24
Reason
Barclays
Price Target
$190 -> $185
2025-10-24
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Icon to $185 from $190 and keeps an Equal Weight rating on the shares. The firm says the company's gross bookings growth give it confidence that its sales growth likely grows low-single-digits next year. However, it has little confidence that Icon's EBITDA will follow.
Leerink
Outperform
to
NULL
downgrade
$235 -> $220
2025-10-23
Reason
Leerink
Price Target
$235 -> $220
2025-10-23
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on Icon to $220 from $235 and keeps an Outperform rating on the shares. The firm thinks Icon's negative stock reaction is due to worries on pricing/gross margins that are not new, and, in Leerink's opinion, are likely overblown relative to the valuation. The firm remains positive on the risk/reward and thinks the improved gross awards/RFP flow should help re-establish a better growth profile. The quarter did not include any negative surprises and the improved gross bookings wins/book-to-bill was encouraging, Leerink adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ICON PLC (ICLR.O) is 14.14, compared to its 5-year average forward P/E of 18.25. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
18.25
Current PE
14.14
Overvalued PE
22.16
Undervalued PE
14.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.25
Undervalued EV/EBITDA
10.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.30
Current PS
0.00
Overvalued PS
2.79
Undervalued PS
1.80
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ICLR News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-10-22 (ET)
2025-10-22
16:29:55
Icon adjusts FY25 EPS forecast to a range of $13.00-$13.20, down from $13.00-$14.00.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Yahoo Finance
PinnedICON Survey Highlights Rising Delays in Clinical Trial Startups, Emphasizing the Importance of Human-Centered Site Activation Solutions

  • Survey Findings: ICON plc's recent survey highlights significant challenges faced by clinical trial sites, including operational bottlenecks, contract and budget delays, and poor communication, with 55% of respondents reporting activation times exceeding 5 months.

  • Need for Improvement: A majority of respondents (66%) frequently encounter contract and budget delays, and 92% believe that sponsors and CROs need to enhance their support, particularly in communication.

  • Actionable Strategies: The accompanying whitepaper outlines strategies for improving trial startup processes, such as implementing site engagement approaches, utilizing predictive analytics, and adopting data-informed site selection methods.

  • Industry Context: The survey reflects a growing concern in the industry, with site pre-selection decline rates increasing from 35% to 47% between 2021 and 2023, emphasizing the urgency of addressing these operational challenges.

[object Object]
Preview
7.5
12-02Businesswire
ICON Reports Clinical Trial Startup Survey, 55% of Respondents Say Activation Time Exceeds 5 Months
  • Survey Reveals Bottlenecks: ICON's recent industry survey indicates that 55% of respondents report activation times exceeding 5 months from site selection, highlighting significant challenges in the clinical trial startup phase that hinder timely access to new therapies.
  • Prevalence of Contract and Budget Delays: 66% of respondents frequently experience contract and budget delays, with 92% identifying these as critical areas for improvement by sponsors and CROs, underscoring the urgent need for enhanced support efficiency in the industry.
  • Communication Quality Needs Improvement: 47% of respondents rated sponsor and CRO communication as average or poor, emphasizing the importance of a site-centric collaborative model to address current communication gaps and accelerate trial processes.
  • Whitepaper Proposes Solutions: ICON's newly released whitepaper outlines actionable strategies, including implementing site engagement approaches that balance alignment with competing priorities, to address rising site attrition rates and promote efficient clinical trial startups.
[object Object]
Preview
2.0
11-22NASDAQ.COM
Icon (ICLR) Stock Surpasses 200-Day Moving Average
  • 52 Week Range: ICLR's stock has a 52-week low of $125.10 and a high of $228.285, with the last trade recorded at $164.56.
  • Market Analysis: The article mentions other stocks that have recently crossed above their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information provided highlights the current performance and volatility of ICLR's stock within the specified time frame.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ICON PLC (ICLR) stock price today?

The current price of ICLR is 185.77 USD — it has decreased -1.07 % in the last trading day.

arrow icon

What is ICON PLC (ICLR)'s business?

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

arrow icon

What is the price predicton of ICLR Stock?

Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ICON PLC (ICLR)'s revenue for the last quarter?

ICON PLC revenue for the last quarter amounts to 2.04B USD, increased 0.63 % YoY.

arrow icon

What is ICON PLC (ICLR)'s earnings per share (EPS) for the last quarter?

ICON PLC. EPS for the last quarter amounts to 0.03 USD, decreased -98.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for ICON PLC (ICLR)'s fundamentals?

The market is revising Upward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by 1.09% over the past three months. During the same period, the stock price has changed by 6.23%.
arrow icon

How many employees does ICON PLC (ICLR). have?

ICON PLC (ICLR) has 41900 emplpoyees as of December 05 2025.

arrow icon

What is ICON PLC (ICLR) market cap?

Today ICLR has the market capitalization of 14.19B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free